Stockholm Ischemic Heart Disease Study

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Stockholm Ischemic Heart Disease Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stockholm Ischemic Heart Disease Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stockholm Ischemic Heart Disease Study

CDC on Stockholm Ischemic Heart Disease Study

Stockholm Ischemic Heart Disease Study in the news

Blogs on Stockholm Ischemic Heart Disease Study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Stockholm Ischemic Heart Disease Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Rim Halaby, M.D. [2]

## Overview

[edit | edit source]

The Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality.

## Study Description

[edit | edit source]

Study Description

Study Design
Allocation | Randomized
Endpoint | Ischemic heart disease mortality
Masking | Open label
Study Details
Primary Purpose |
Condition | Survivors of a myocardial infarction
Study Arms | Clofibrate and nicotinic acid
Control
Population Size | 555 subjects

## Publications

[edit | edit source]

The Stockholm Ischemic Heart Disease study revealed a 36% decrease in ischemic heart disease mortality among patients who received the treatment vs control. The treatment effect on ischemic heart disease mortality was mostly related to the triglycerides plasma concentration, particularly among patients with a triglyceride plasma concentration higher than 1.5 mmol/l and those who had a decrease in the serum triglyceride by at least 30%.[1]

## References

[edit | edit source]

1. ↑ Carlson LA, Rosenhamer G (1988). "Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid". Acta Med Scand. 223 (5): 405–18. PMID 3287837.

* v
* t
* e

Lipopedia

Basic Science|

Cholesterol • Triglyceride

Lipoprotein metabolism and transport

Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X

Apolipoprotein: APOA (1, 2, 4,  5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a)

Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor

Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1

Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1

Lipoprotein Disorders|

Lipoprotein disorders

Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V)

Secondary lipoprotein disorders

Abnormal Laboratory Lipid Profile|

Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL

High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template